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The effect of long-chain n-3 PUFA on the metabolism of apoB100-containing lipoprotein in diabetic subjects is not fully understood. The objective
of the present study was to determine the effect of a daily intake of 1080mg EPA and 720mg DHA for diabetic subjects on the kinetics of
apoB100-containing lipoprotein in the fasting state. A kinetic study was undertaken to determine the mechanisms involved in the effects of
n-3 fatty acids in terms of a decrease in triacylglycerol level in type 2 diabetic patients. We have studied the effect of fish oils on the metabolism
of apoB100 endogenously labelled by [5,5,5-2H3]-leucine in type 2 diabetic patients in the fasting state. The kinetic parameters of apoB100 in
VLDL, intermediate-density lipoprotein and LDL were determined by compartmental modelling in five diabetic subjects before and 8 weeks
after n-3 fatty acid treatment. Treatment did not change the plasma cholesterol level (0·801 (SD 0·120) v. 0·793 (SD 0·163) mmol/l) but lowered
the plasma triacylglycerol level (1·776 (SD 0·280) v.1·356 (SD 0·595) mmol/l; P,0·05). Treated patients showed a decrease in VLDL apoB100
concentration (0·366 (SD 0·030) v.0·174 (SD 0·036) g/l; P,0·05) related to a decrease in VLDL 1 production (1·49 (SD 0·23) v.0·44 (SD 0·19)
mg/kg per h; P,0·05) and an increase in the VLDL conversion rate (0·031 (SD 0·024) v.0·052 (SD 0·040) per h; P,0·05), with no change in frac-
tional catabolic rates. Treatment led to a higher direct production of intermediate-density lipoprotein (0·02 (SD 0·01) v.0·24 (SD 0·12) mg/kg per h;
P,0·05). In conclusion, the present study, conducted in the fasting state, showed that supplementation with n-3 fatty acids in type 2 diabetic
patients induced beneficial changes in the metabolism of apoB100-containing lipoprotein.
n-3 fatty acids: apoB100: Kinetic analysis: Modelling: Diabetes
The relationship between increased plasma cholesterol con-
centration and the development of atherosclerosis has been
demonstrated in many studies (Kannel et al. 1971). Although
the role of hypertriacylglycerolaemia has been controversial, it
is now accepted as a risk factor for CHD (Zilversmit, 1979;
Austin & Hokanson, 1994). This atherogenic pathway
involves the uptake of triacylglycerol-rich lipoprotein
(Fielding et al. 1979; Gianturco et al. 1980) by the apoB48
receptor of macrophages (Brown et al. 2000), leading to
their rapid conversion into foam cells.
Hypertriacylglycerolaemia is frequently associated with
type 2 diabetes and could contribute to the strong development
of atherosclerosis in this disease (Goldberg, 2001). Previous
studies have already underlined that the insulin resistance
observed in type 2 diabetes is associated with an overproduc-
tion of apoB100-containing lipoproteins and reduced LDL and
VLDL catabolism (Duvillard et al. 2000; Ouguerram et al.
2003).
Epidemiological studies in Inuits have suggested that
marine oils rich in n-3 fatty acids are hypolipidaemic and
anti-atherogenic (Kromann & Green, 1980). In addition to
their anti-inflammatory, vasodilatory and antihypertensive
effects (Lichtenstein et al. 1998), n-3 fatty acids are able to
decrease triacylglycerol levels in animals (Harris, 1996) and
human subjects (Connor et al. 1993; Harris, 1996). The
effect on LDL cholesterol is more controversial depending
on the dose used, the duration of treatment and the disease
(Farmer et al. 2001).
Numerous in vivo kinetic studies in healthy human subjects
(Connor et al. 1993) and animals (Harris, 1996) have shown
that this effect is associated with a decrease in VLDL
apoB100 concentration related to a reduction in production.
As in normolipidaemic subjects, the n-3 fatty acids in diabetic
patients lead to a lower plasma triacylglycerol level, but the
underlying mechanisms are not fully understood.
A study involving five type 2 diabetic patients was performed
by Fisher et al. (1998) on apoB100-containing lipoproteins and
reported that the response to n-3 fatty acids was mainly a
decrease in VLDL apoB100 secretion and an increase in inter-
mediate-density lipoprotein (IDL) and LDL production. In that
study, the increase in LDL production with no change of frac-
tional catabolic rate led to an increase in LDL mass. However,
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the study was conducted in feeding subjects, which implies a
possible acute effect of n-3-rich chylomicrons and their rem-
nants on apoB100 metabolism (Zheng et al. 2001; Maldonado
et al. 2003). Moreover, in that study (Fisher et al. 1998), the
authors only compared the effect of n-3 to n-6 fatty acids, two
acids known to influence lipid homeostasis (Mekki et al. 2002;
Zheng et al. 2002). Such a comparison couldmask some specific
effects of n-3 fatty acids.
The purpose of the present study was to investigate the
effect of fish oils on the metabolism of apoB100 in type 2 dia-
betic patients. This study was conducted in the fasting state to
avoid the acute influence of chylomicrons and their remnants
on apoB100 metabolism.
Methods
Subjects
Five patients with type 2 diabetes and dyslipidaemia (Table 1)
were included in the study. Insulin treatment was an exclusion
criterion. They had not been taking any medication that could
affect carbohydrate or lipid metabolism for at least 1month
before the study. Patients had been treated with either sulpho-
nylureas or biguanides for at least 3 months and were
instructed by a dietitian to follow a weight-maintenance diet,
(composed of (% energy): carbohydrate 45; fat 35; protein
20) for at least 1 week prior to the study. Insulin resistance
was assessed by the insulin sensitivity index (homeostasis
model assessment; Matthews et al. 1985). The experimental
protocol was approved by the ethical committee of Nantes
University Hospital, and written informed consent was
obtained before the study was started.
Experimental protocol
Five diabetic patients underwent a basal kinetic study the
day before the start of the treatment. They then received
six capsules/d MaxEPA (Pierre Fabre Sante´, Castres, France),
a concentrate of n-3, long-chain PUFA from fish oil, over 8
weeks. Each MaxEPA capsule contained 1000mg methyl
ester fatty acids, providing 180mg EPA (20 : 5-v3), 120mg
DHA (22 : 6-v3) and 1·75mg a-tocopherol acetate. The
second kinetic study was carried out at the end of the treatment.
The kinetic protocol was similar to that previously
described (Ouguerram et al. 2003). Briefly, the endogenous
labelling of apoB100 was carried out by constant infusion of
[5,5,5-2H3]-leucine in subjects fasted overnight for 12 h
prior to the study who remained fasting during the entire pro-
cedure. Each subject received intravenously a prime of
10mmol/kg tracer immediately followed by a constant tracer
infusion (10mmol/kg per h) for 14 h. Venous blood samples
were drawn into EDTA tubes (Venoject, Paris, France) at
baseline and at 15, 30 and 45min, 1, 1·5, 2 and 2·5 h, and
then hourly until 14 h. Sodium azide, an inhibitor of bacterial
growth, and Pefabloc SC (Interchim, Montluc¸on, France), a
protease inhibitor, were added to blood samples at a final con-
centration of 1·5 and 0·5mmol/l, respectively.
Analytical procedures
Isolation and measurement of enrichment of lipoprotein con-
taining apoB100. Isolation of lipoproteins and measurement
of leucine enrichment in apoB100 have previously been
described (Ouguerram et al. 2003). Briefly, lipoproteins
were separated by density-gradient ultracentrifugation, and
apoB100 was isolated by sodium dodecylsulfate polyacryl-
amide gel electrophoresis. Apo bands were dried under a
vacuum and then hydrolysed. The amino acids were purified
by cation-exchange chromatography and then esterified and
derivatised. Electron-impact GC–MS was performed on a
5891 A gas chromatograph connected with a 5971 A quadru-
pole mass spectrometer (Hewlett Packard Co., Palo Alto, CA,
USA). The isotopic ratio was determined by selected ion-
monitoring at m/z of 282 and 285. Calculations of apoB100
kinetic parameters were based on the tracer:tracee mass ratio
(Cobelli et al. 1992).
Table 1. Clinical characteristics of type 2 diabetic patients before (base) and after (post) supplementation with MaxEPA (Pierre Fabre Sante´, Castres,
France)
Subject Age (years) BMI (kg/m2) HbA1c (%) Insulin MU/l
Glucose
(mmol/l)
Homeostasis model
assessment
Plasma cholesterol
(mmol/l)
Plasma
triacylglycerol
(mmol/l)
1 Base 37 32·2 6·1 16·4 8·7 6·3 0·820 1·873
Post 30·1 5·2 6·5 6·1 1·8 0·615 0·630
2 Base 54 31·8 5·2 ND 7·1 ND 0·789 1·628
Post 32·4 5·6 ND 7·6 ND 0·828 1·549
3 Base 55 26·6 5·1 26·9 7·7 9·2 0·971 1·689
Post 27·0 5·9 22·0 7·1 6·9 0·848 1·260
4 Base 36 33·3 8·7 12·0 13·0 6·9 0·639 1·470
Post 32·9 9·1 15·1 13·3 8·9 0·662 1·120
5 Base 65 29·0 11·1 17·8 11·3 8·9 0·782 2·205
Post 28·6 8·6 17·9 10·5 8·3 1·022 2·240
Mean base 49 30·6 7·2 18·3 9·5 7·8 0·801 1·776
SD 13 2·7 2·6 6·3 2·5 1·4 0·120 0·280
Mean post – 30·2 6·9 15·4 8·9 6·5 0·793 1·356*
SD – 2·5 1·8 6·6 3·0 3·2 0·163 0·595
ND, not determined.
*P,0·05, post v. base.
For details of subjects and procedures, see this page.
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Measurements of lipids and apoB100. Cholesterol and
triacylglycerol concentrations were measured using
commercially available enzymatic kits (Boehringer Mannheim
GmbH, Mannheim, Germany) at three different sampling
times. ApoB100 concentrations were obtained in lipoprotein
fractions by combining selective precipitation and MS
(Beghin et al. 2000). The percentage recovery of cholesterol,
triacylglycerol and apoB100 after centrifugation was higher
than 85.
Modelling. Kinetic analysis of tracer:tracee ratios was
achieved using computer software for simulation, analysis
and modelling. The model used (Fig. 1) is the same as that
previously developed for apoB100 metabolism in diabetic
patients (Ouguerram et al. 2003). This model takes into
account heterogeneity in VLDL. In this model, a forcing func-
tion, corresponding to the time course of plasma leucine
enrichment, was used to drive the appearance of leucine
tracer in the apoB100 of the different lipoprotein fractions.
ApoB100 enters into plasma through VLDL secretion and
the direct production of IDL and LDL. Direct removal of
apoB100 occurs from VLDL1 (k(0,10)), VLDL2 (k(0,20)),
VLDL remnant (VLDLR) (k(0,11)), IDL (k(0,30)) and LDL
(k(0,40)). ApoB100 transfer to higher-density lipoproteins
occurs by conversion for VLDL1 (k(20,10), k(11,10)),
VLDL2 (k(30,20), k(40,20)) and IDL (k(40,30)). The methods
provided identified values and standard deviations as obtained
by iterative least squares fitting for individual kinetic par-
ameters. Standards deviations were less than 30% for most
of the parameters (data not shown). The use of more complex
models did not provide a significant improvement in the fitting
from the F test and Akaike information criterion (Pont et al.
1998).
For comparison between the two states (before and after n-3
treatment), the VLDL1, VLDL2 and VLDLR data were
presented as the VLDL conversion rate and VLDL direct
removal rate. The VLDL conversion rate was calculated as
VLDL2 conversion flux divided by total VLDL mass. The
direct removal of VLDL was calculated as the flux of
VLDL1, VLDL2 and VLDLR direct removal divided by the
total VLDL mass (Ouguerram et al. 2003). The VLDL frac-
tional catabolic rate represented the sum of the conversion
and direct removal rates.
As all our patients were obese, pools of apoB100 in the
plasma or in VLDL, IDL and LDL were calculated by multi-
plying the apoB100 concentration by 0·037 (l/kg), assuming a
plasma volume of 3·7% of body weight (Dagher et al. 1965).
The apoB100 production rate in mg/kg per h represented the
product of fractional catabolic rate and pool size of
apoB100 in the lipoprotein fractions.
Statistical analysis. Results are reported as means and
standard deviations. Wilcoxon’s signed rank-test, performed
with Statview F-4·5 (Abacus Concept, Berkeley, CA, USA)
was used to compare data before and after treatment. A two-
tailed probability level of 0·05 or less was accepted as statisti-
cally significant.
Results
Concentrations of lipids and apoB100 in plasma and in lipo-
protein fractions are shown in Tables 1 and 2 before and
after n-3 administration. Compared with the basal state, a
lower concentration of plasma triacylglycerol (1·776 (SD
0·280) mmol/l v. 1·356 (SD 0·595) mmol/l; P,0·05) was
observed. This decrease was related to a fall in VLDL1
triacylglycerol (1·006 (SD 0·271) mmol/l v. 0·534 (SD 0·289)
mmol/l; P,0·05). Treatment did not significantly affect
plasma total cholesterol. A decrease of apoB100 in VLDL
(0·366 (SD 0·030) v. 0·174 (SD 0·036) g/l; P,0·005) related
to a fall in VLDL1 apoB (0·244 (SD 0·015) v. 0·075
(SD 0·050) g/l; P,0·005) was observed with treatment.
1
Plasma
leucine
10
VLDL1
20
VLDL2
30
IDL
40
LDL11
VLDLR
Delay of apoB
production
k(20,10)
k(0,20)
k(0,30)
k(0,40)
k(0,10) 
k(11,10)
k(40,30)
k(30,20)
k(40,20)
k(0,11)
Fig. 1. Model of apoB100-containing lipoprotein metabolism. For details of subjects and procedures, see p. 101. IDL, intermediate-density lipoprotein; VLDLR;
very low-density lipoprotein R.
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The effect on LDL apoB100 was variable between subjects (a
decrease in one subject and an increase in the others), leading
to a slight but not significant increase in LDL apoB100. As
shown in Table 1, no effect on BMI, fasting plasma glucose,
homeostasis model assessment or HbA1c concentration was
observed with treatment.
Lipoprotein kinetics
The time course of enrichment in VLDL, IDL and LDL
apoB100 for subject 3 before and after n-3 treatment is
shown in Fig. 2. Model fitted lines and experimental points
showed close agreement. The masses of B100 calculated by
SAAMII in each compartment were also similar to those
chemically measured (data not shown). Kinetic parameters
are shown in Table 2.
Compared with the basal situation (Table 3), treatment with
n-3 significantly reduced the overall production of apoB100
(1·73 (SD 0·28) v. 0·97 (SD 0·13) mg/kg per h; P,0·05;
Table 2). This decrease was related to VLDL1 apoB100 pro-
duction (1·49 (SD 0·23) v.0·44 (SD 0·19) mg/kg per h;
P,0·05). In parallel to this decrease, treatment increased the
direct production of IDL (0·02 (SD 0·01) v.0·24 (SD 0·12)
mg/kg per h; P,0·05) and LDL (0·07 (SD 0·05) v.0·18 (SD
0·17) mg/kg per h; NS). No effect on the uptake of VLDL
was observed with treatment, but the conversion rate was sig-
nificantly increased (0·031(SD 0·024) v.0·052 (SD 0·04) per h;
P,0·05), and VLDL were channelled more towards higher-
density lipoproteins (data not shown). The fractional catabolic
rates of IDL and LDL were not affected by the treatment.
Discussion
The aim of the present study was to examine, in type 2 dia-
betes, the effect of n-3 fatty acids (1·8 g/d) on the metabolism
of apoB100-containing lipoprotein. Analyses were performed
using stable isotopes on fasting subjects to avoid any acute
influence of n-3-containing chylomicrons and chylomicron
remnants on apoB100 metabolism. The model used in this
study includes heterogeneity of VLDL and is consistent, as
shown by the low CV of parameters. The present study
showed that, in type 2 diabetes, n-3 fatty acids lowered triacyl-
glycerolaemia by decreasing apoB100 VLDL production and
by stimulating VLDL conversion to IDL. The heterogeneous
response to n-3 fatty acids led to a non-significant increase
Table 2. Lipoprotein composition in diabetic subjects before and during treatment with MaxEPA (Pierre Fabre Sante´, Castres, France)
VLDL1 VLDL2 IDL LDL
Subject
TC
(mmol/l)
TG
(mmol/l)
ApoB
(g/l)
TC
(mmol/l)
TG
(mmol/l)
ApoB
(g/l)
TC
(mmol/l)
TG
(mmol/l)
ApoB
(g/l)
TC
(mmol/l)
TG
(mmol/l)
ApoB
(g/l)
1 Base 0·023 1·050 0·249 0·046 0·368 0·134 0.046 0.088 0·198 0.372 0.149 0·863
Post 0·112 0·306 0·095 0·054 0·254 0·81·0 0.039 0.088 0·106 0.395 0.193 0·766
2 Base 0·015 0·569 0·269 0·008 0·289 0·138 0.012 0.026 0·026 0.352 0.193 0·526
Post 0·019 0·184 0·033 0·015 0·131 0·138 0.027 0.070 0·068 0.201 0.184 0·610
3 Base 0·066 1·085 0·233 0·027 0·166 0·100 0.046 0.175 0·129 0.178 0.175 0·463
Post 0·058 0·560 0·151 0·035 0·166 0·082 0.046 0.096 0·124 0.379 0.306 0·793
4 Base 0·097 1·041 0·233 0·043 0·245 0·112 0.039 0.070 0·21·2 0.352 0.193 0·446
Post 0·066 0·779 0·028 0·066 0·350 0·105 0.074 0.149 0·067 0.402 0.193 0·580
5 Base 0·074 1·295 0·237 0·039 0·324 0·128 0.039 0.079 0·57·3 0.302 0.219 0·576
Post 0·050 0·840 0·068 0·058 0·254 0·091 0.070 0.175 0·088 0.348 0.219 0·688
Base
Mean 0·054 1·006 0·244 0·031 0·280 0·122 0.035 0.088 0·086 0.310 0.184 0·575
SD 0·035 0·271 0·015 0·015 0·079 0·016 0.015 0.053 0·076 0.077 0.026 0·169
Post
Mean 0·062 0·534* 0·075** 0·046 0·228 0·099 0.050 0.114 0·090 0.344 0.219 0·687
SD 0·035 0·289 0·050 0·019 0·088 0·024 0.019 0.044 0·024 0.081 0.053 0·093
IDL, intermediate-density lipoprotein; TC, total cholesterol; TG, triacylglycerol.
*P,0·05, **P,0·005.
For details of subjects and procedures, see p. 101.
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Fig. 2. Time course of enrichment of VLDL 1 ( ), VLDL 2 ( ), intermediate-
density lipoprotein (X) and LDL ( ) apoB100 in a representative diabetic
subject (number 3) before (A) and after (B) supplementation with MaxEPA
(Pierre Fabre Sante´, Castres, France). For details of subjects and pro-
cedures, see p. 101.
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of LDL in spite of a higher conversion rate of VLDL and a
non-significant increase of direct LDL production. Treatment
with n-3 acids did not affect diabetic control.
In type 2 diabetic patients, the kinetics of apoB100 meta-
bolism is well documented (Duvillard et al. 2000; Ouguerram
et al. 2003). Briefly, in mild diabetes, an overproduction of
VLDL and impaired lipolysis leads to hypertriacylglycerolae-
mia (Duvillard et al. 2000), whereas in moderate or severe
diabetes, a delay in LDL catabolism is also reported, explain-
ing the combined hyperlipidaemia (Kissebah et al. 1983;
Ouguerram et al. 2003).
The present study is the first kinetic study on diabetic subjects
performed in the fasting state that has compared the effect of n-3
fatty acid treatment to a basal diet. To distinguish a chronic
effect of n-3 fatty acids and an acute effect of n-3 absorption,
the study was performed in the fasting state, in contrast to a pre-
vious study by Fisher et al. (1998). It is well known that chylo-
microns and their remnants enriched in n-3 fatty acids (Zheng
et al. 2001;Maldonado et al. 2003) or a direct delivery of dietary
n-3 PUFA to the liver (Wang et al. 1993) reduces hepatic VLDL
synthesis. A study design performed in the feeding state did not
allow a discrimination between a short-term effect consequent
on absorptive flux and a long-term effect consequent on a
change in cell membrane composition. To avoid such confusion,
the present kinetic study was conducted in the fasting state.
The effect of fish oil on plasma lipid and apo concentration has
been well documented in animal (Harris, 1996) and in healthy
(Connor et al. 1993) and hypertriacylglycerolaemia (Fisher
et al. 1998; Chan et al. 2003) human subjects. In these studies,
dramatic reductions in plasma triacylglycerol levels occurred,
with an inconsistent response in plasma total cholesterol that
varied from study to study depending on the diet previously
administrated and mainly with the nature of the fatty acids
added, although alsowith the dose administered and the duration
of treatment (Fisher et al. 1998; Farmer et al. 2001). The mech-
anisms underlying these effects were largely reported in animals
(Harris, 1996), and healthy human subjects (Connor et al. 1993;
Harris, 1996), but data on diabetic subjects have been missing,
particularly in terms of the lack of a kinetic study. Only one
study had previously been performed on diabetic subjects
(Fisher et al. 1998), but the data compared n-6 and n-3 treat-
ments without making any comparison with the basal state.
In the present study, n-3 acids significantly decreased tria-
cylglycerolaemia. This fall is related to lower VLDL and
especially VLDL1 production, as previously reported in
other studies (Fisher et al. 1998; Chan et al. 2003). This
was not related to a change in the abundance of mRNA for
apoB100 (Zheng et al. 2001). However, an enhanced intra-
cellular degradation of apoB100 was shown in primary rat
hepatocytes (Wang et al. 1993). One other major effect of
n-3 is the inhibition of triacylglycerol synthesis by decreasing
the activity of acyl-CoA:1.2-diacylglycerol acyltransferase
(Rustan et al. 1988) and increasing their triacylglycerol oxi-
dation (Yamazaki et al. 1987). Several studies have also
showed that n-3 fatty acids regulate the expression of numer-
ous genes (Clarke, 2004) involved in the suppression of fatty
acid synthesis. As VLDL secretion depends on the available
synthesised triacylglycerol (Wu et al. 1996), the inhibition
of fatty acid and triacylglycerol synthesis could result in an
increased degradation of apoB100. It also has to be
emphasised that the present study was performed in the fasting T
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state, suggesting that VLDL synthesis was not due to an acute
inhibition by n-3-enriched chylomicrons but probably to pro-
found and chronic changes in n-3 concentration in the hepato-
cytes after long-term treatment.
We did not observe any effect of n-3 fatty acids on the VLDL,
IDL and LDL fractional catabolic rates. Although the absence of
a significant effect on VLDL and IDL fractional catabolic rate
has previously been reported (Fisher et al. 1998; Chan et al.
2003), data on the LDL fractional catabolic rate are conflicting
(Ventura et al. 1989; Spady et al. 1995; Schectman et al.
1996; Vasandani et al. 2002; Theobald et al. 2004). Feeding
fish oil stimulated the clearance of LDL in rats (Ventura et al.
1989) and mice (Vasandani et al. 2002) but decreased the recep-
tor-mediated clearance of LDL in hamsters (Spady et al. 1995),
primates (Schectman et al. 1996) and human subjects (Theobald
et al. 2004). This decrease could be a result of either decreased
binding of LDL to the LDL receptor or decreased expression
of the LDL receptor. The decrease in the number of specific
binding sites for acetyl LDL in peritoneal macrophages in rat
by EPA was reported by Saito et al. (1992). LDL undergo a
change in physical properties in response to n-3 fatty acids
(Bell et al. 1996), which renders them more susceptible to oxi-
dation (Whitman et al. 1994; Nestel et al. 1997). Although
LDL generated after n-3 supplementation are susceptible to oxi-
dation (Whitman et al. 1994; Nestel et al. 1997), they are not
atherogenic. In the present study, as in others (Fisher et al.
1998), LDL have been analysed as a one homogenous pool, so
the fractional catabolic rate measured is a mean of that for all
LDL subpopulations. Although Rivellese et al. (2003) observed
nomodification in LDL size on n-3 supplementation, it might be
interesting to examine their effect on the kinetics of small and
large LDL.
In the present study, we showed that n-3 fatty acids
increased the conversion of VLDL to IDL but not the conver-
sion of IDL to LDL. The effect of n-3 fatty acids on lipopro-
tein lipase (LPL) activity was reported in animals (Huff &
Telford, 1989), healthy human subjects (Kasim-Karakas et al.
1995; Harris et al. 1997) or insulin-resistant human subjects
(Chan et al. 2003). Dietary n-3 fatty acids have been also
shown to accelerate chylomicron triacylglycerol clearance in
rats (Rahman et al. 2000). Supplementation with n-3 enhances
chylomicron triacylglycerol clearance by increasing LPL and
hepatic lipase activity in healthy subjects but only LPL
activity in hypertriacylglycerolaemia patients (Harris et al.
1997). An increase in post-heparin LPL activity and the
level of LPL mRNA in the adipose tissue of subjects with
an atherogenic lipoprotein phenotype has been reported with
n-3 acids (Khan et al. 2002). In parallel to a decrease of
VLDL production, n-3 fatty acids shift the channelling of
apoB100 from large VLDL to small VLDL, IDL and LDL.
This could be explained by the secretion of small VLDL
with a lower triacylglycerol:apoB ratio, which are rapidly con-
verted to LDL (Lu et al. 1999).
In the present study, we did not observe any difference in
the triacylglycerol:apoB ratio between the two states (data
not shown). This discrepancy could be explained by the
lower dose of n-3 used in our study. In Fisher et al.’s
(1998) study, the authors did not observe any change in
lipoprotein conversion. In that study, the comparison was
against a diet enriched in n-6 fatty acids, and any compari-
son with a basal diet was missing. Although the major effect
of n-6 fatty acids is to lower plasma cholesterol level
(Kasim-Karakas et al. 1995), they also increase plasma
triacylglycerol hydrolysis as n-3 fatty acids (Mekki et al.
2002). Therefore, the comparison between n-3 and n-6
fatty acids does not allow an assessment of the actual mag-
nitude of the effect of n-3. Because n-3 fatty acids affect
VLDL conversion into IDL, but not the conversion of
IDL into LDL, we suggest that LPL and hepatic lipase
are not regulated by similar pathways (Peinado-Onsurbe
et al. 1992; Ouguerram et al. 2003).
In conclusion, n-3 fatty acids were effective in lowering
triacylglycerolaemia in individuals with type 2 diabetes
patients via the suppression of VLDL production and the
stimulation of its conversion into LDL. As diabetic subjects
also respond to statins known to stimulate LDL uptake
(Ouguerram et al. 2003), combined therapy could be rec-
ommended in case of mixed dyslipidaemia.
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